stockrowICON PLC
ICLR Healthcare Diagnostics & Research
ICON PLC’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.76% from fiscal 2024.
- Revenue
- −2.86%
- EPS
- +143.2%
- Free cash flow
- −8.01%
- Total debt
- −0.86%
Quarter to September 2026, against a year earlier
Follow ICLR
Alert me
ICON PLC (ICLR) Total debt
ICON PLC's total debt at the end of fiscal 2025 was $3.4B, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $3.4B. Over the past ten years it has ranged from $348.3M (fiscal 2015) to $5.4B (fiscal 2021); the current reading is higher than 64% of that period. ICON PLC ranks 8th of 46 Diagnostics & Research companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $3.4B | (0.69%) |
| FY2024 | $3.4B | (9.25%) |
| FY2023 | $3.8B | (18.88%) |
| FY2022 | $4.7B | (14.39%) |
| FY2021 | $5.4B | 1,359.50% |
| FY2020 | $372.5M | (12.70%) |
| FY2019 | $426.6M | 22.15% |
| FY2018 | $349.3M | 0.11% |
| FY2017 | $348.9M | 0.11% |
| FY2016 | $348.5M | 0.06% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $3.4B | (0.34%) |
| Jun 2026 | $3.4B | (0.17%) |
| Mar 2026 | $3.4B | (0.17%) |
| Dec 2025 | $3.4B | (0.17%) |
| 41 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| DGX Quest Diagnostics Incorporated compare | $5.6B |
| LH Labcorp Holdings Inc. compare | $5.3B |
| ICLR ICON PLC | $3.4B |
| RVTY Revvity Inc. compare | $2.6B |
| CRL Charles River Laboratories International, Inc. compare | $2.4B |
| ILMN Illumina, Inc. compare | $1.8B |
| QGEN QIAGEN N.V. compare | $1.6B |
| GH Guardant Health, Inc. compare | $1.5B |
| MEDP Medpace Holdings, Inc. compare | $163.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on ICLR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement